Sandoz Group AG held its Capital Markets Day at the London Stock Exchange on 8 September 2026, laying out a multi-year growth strategy centred on biosimilars called Bio100.
The company announced an ambition to expand its biosimilar portfolio to more than 100 products by 2040, up from 13 currently. Loss-of-exclusivity coverage in biosimilars is targeted to rise to around 80% from 2035, compared with approximately 50% today.
Sandoz reaffirmed its existing mid-term outlook through 2028 and introduced a new financial framework covering 2025 to 2030. The company targets mid-to-high single-digit compound annual growth in net sales at constant currencies over that period, with a core EBITDA margin of 25-27% by 2030. These figures include the impact of GLP-1 products.
Looking further ahead, Sandoz aims to more than double net sales from 2025 levels by 2035 through Bio100, with a core EBITDA margin exceeding 30%. That sales target excludes the impact of GLP-1 products.
In 2025, Sandoz recorded net sales of USD 11.1 billion. The company employs more than 20,000 people across 100 nationalities and currently markets approximately 1,300 medicines.
CEO Richard Saynor said: "Sandoz begins its next growth phase from a position of strength, built on a strong track record and a proven global platform. Our Bio100 ambitions are set to position biosimilars to become the majority of our sales, broadening access for patients while creating significant value for shareholders."
The Capital Markets Day event took place at the London Stock Exchange, beginning at 13:30 UK time and concluding around 17:00. Speakers included Chairman Gilbert Ghostine, CEO Richard Saynor, CFO Remco Steenbergen, Chief Commercial Officer Rebecca Guntern, and presidents leading the biosimilar development and supply, Europe, and international divisions.
Sandoz also announced it will host an investor and analyst site visit at its new biosimilar hub in Slovenia on 9-10 November. Attendance is by invitation only and the event will not be webcasted.
The company emphasized that its strategy is supported by a "leading biosimilar pipeline, a scalable, flexible and cost-competitive biosimilar development, manufacturing and supply network, [and] best-in-class commercial engines."
